CRC Research Update — September 05, 2026
Today's colorectal cancer research highlights
adjuvant
A collection of 37 issues
Immune Recovery After Surgery Linked to ctDNA Minimal Residual Disease
Skip to content
The CRC Digest
Immune Recovery After Surgery Linked to ctDNA Minimal Residual Disease
A prospective study of 1,000 stage II-III CRC patients found that distinct perioperative immunocircadian recovery trajectories were associated with postoperative ctDNA-based minimal residual disease and long-term survival outcomes. (Surgery)
This content is informational
CRC Research Update — August 31, 2026
Today's colorectal cancer research highlights
Phase III trial shows circulating tumor DNA methylation monitoring can guide postoperative surveillance in nonmetastatic colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Phase III trial shows circulating tumor DNA methylation monitoring can guide postoperative surveillance in nonmetastatic colorectal cancer
The prospective, randomized FIND trial used dynamic ctDNA methylation monitoring to personalize follow-up care after surgery in stage I-III patients. (Journal of Clinical Oncology)
This
CRC Research Update — August 27, 2026
Today's colorectal cancer research highlights
Circulating Tumor DNA Shows Promise for Guiding Adjuvant Therapy After Curative Surgery
Skip to content
The CRC Digest
◇ RESEARCH
Circulating Tumor DNA Shows Promise for Guiding Adjuvant Therapy After Curative Surgery
A review examines how circulating tumor DNA (ctDNA) offers a dynamic readout of molecular residual disease in the postoperative period, potentially guiding adjuvant treatment decision-making in stage II (15-20% recurrence) and
ctDNA Testing May Identify Who Benefits from Chemotherapy After Liver Metastasis Surgery
Skip to content
The CRC Digest
ctDNA Testing May Identify Who Benefits from Chemotherapy After Liver Metastasis Surgery
An overall survival analysis of the phase II GALAXY study presented at ESMO GI 2026 suggests that circulating tumor DNA for molecular residual disease tracking could help identify patients with colorectal cancer
CRC Research Update — August 24, 2026
Today's colorectal cancer research highlights
Study Identifies Risk Factors for Serious Intestinal Side Effect With CAPOX Chemotherapy
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Study Identifies Risk Factors for Serious Intestinal Side Effect With CAPOX Chemotherapy
Researchers examined the incidence and risk factors of non-neutropenic enterocolitis—a serious intestinal inflammation—in colorectal cancer patients receiving adjuvant capecitabine and oxaliplatin (CAPOX) chemotherapy. (Clinical Colorectal Cancer)
This
CRC Research Update — August 18, 2026
Today's colorectal cancer research highlights